On the last day of 2020, the Chinese regime approved a COVID-19 vaccine developed by state-run firm Sinopharm. However, international experts are skeptical about its efficacy and safety, as little clinical data has been released thus far. A Chinese top expert also expressed reservations about it. On Dec. 31, 2020, China’s State Council announced at a press conference that Sinopharm’s inactivated vaccine had been granted “conditional approval” by China’s Drug Administration. The vaccine had an efficacy rate of 79.34 percent, according to state media reports. By comparison, the Pfizer COVID-19 vaccine has an efficacy rate of 95 percent and the Moderna vaccine 94.1 percent. Lack of Supporting Data Sinopharm did not provide any breakdown of its clinical trial data, nor disclose the size of its testing sample. In an interview with The Epoch Times, former U.S. Army Research Institute virology researcher Dr. Sean Lin said that without transparent data, it …